60 Degrees Pharma Files Proxy Statement

TL;DR

60 Degrees Pharma filed their proxy statement for the Nov 6 meeting. Standard stuff, no major surprises yet.

AI Summary

60 Degrees Pharmaceuticals, Inc. filed a definitive proxy statement on October 15, 2024, for their annual meeting on November 6, 2024. The company is seeking shareholder approval for various corporate matters, as is standard for a DEF 14A filing. No specific financial proposals or executive compensation details are highlighted in this initial filing.

Why It Matters

This filing outlines the agenda for 60 Degrees Pharmaceuticals' upcoming shareholder meeting, which could include votes on board members or corporate governance changes that impact the company's direction.

Risk Assessment

Risk Level: low — This is a routine proxy filing, not indicating any immediate financial distress or significant new risks.

Key Numbers

• 20241015 — Filing Date (Date the proxy statement was submitted to the SEC.)
• 20241106 — Meeting Date (Date of the shareholder meeting for which this proxy is being solicited.)

Key Players & Entities

• 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
• 0001213900-24-087749 (filing_id) — Accession Number
• 20241015 (date) — Filing Date
• 20241106 (date) — Meeting Date

FAQ

Key Financial Figures

• $0.0001 — ompany’s common stock, par value $0.0001 per share, under applicable rules and r

Filing Documents

• ea0215478-02.htm (DEF 14A) — 601KB
• tproxy_001.jpg (GRAPHIC) — 1254KB
• tsixty_logo.jpg (GRAPHIC) — 77KB
• tsixty_logo1.jpg (GRAPHIC) — 77KB
• 0001213900-24-087749.txt ( ) — 2543KB

From the Filing

DEF 14A 1 ea0215478-02.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________ SCHEDULE 14A _____________________________________ Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant   ☒ Filed by a Party other than the Registrant   Check the appropriate box:   Preliminary Proxy Statement   Confidential, for Use of the Commission Only (as permitted by Rule 14a -6 (e)(2)) ☒   Definitive Proxy Statement   Definitive Additional Materials   Soliciting Material under §240.14a -12 60 DEGREES PHARMACEUTICALS, INC. (Name of Registrant as Specified In Its Charter) N / A (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒   No fee required   Fee paid previously with preliminary materials   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a -6 (i)(1) and 0 -11 .   Table of Contents 60 DEGREES PHARMACEUTICALS, INC. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 https: // 60degreespharma.com October 15, 2024 Dear Fellow Stockholders: On behalf of your Board of Directors, we cordially invite you to attend the 2024 Special Meeting of Stockholders of 60 Degrees Pharmaceuticals, Inc. (the “Special Meeting”). The Special Meeting will be held on November 6, 2024, at 12:30 p.m. Eastern Time, in a virtual meeting format only and conducted via live audio webcast over the telephone to enable our stockholders to participate from locations around the world. Stockholders will NOT be able to attend the Special Meeting in person. The Special Meeting will be accessible only over the telephone. Please see “Attending the Virtual Special Meeting” in the proxy statement (“Proxy Statement”) accompanying this letter for information on how to obtain the proxy materials, attend, ask questions and vote at the Special Meeting. We are making available to you the accompanying Notice of Special Meeting of Stockholders (“Notice”), Proxy Statement and form of proxy card or voting instruction form on or about October 15, 2024. We are pleased to furnish proxy materials to stockholders primarily over the internet. We believe that this process expedites stockholders’ receipt of proxy materials, lowers the costs of our Special Meeting and conserves natural resources. On or about October 15, 2024, we mailed to our stockholders a Notice of Internet Availability of Proxy Materials (the “Internet Availability Notice”) that includes instructions on how to access our Proxy Statement and how to vote over the telephone. The Internet Availability Notice also includes instructions on how you can receive a paper copy of your Special Meeting materials, including the Notice, Proxy Statement and proxy card or voting instruction form. If you elected to receive your Special Meeting materials by mail, the Notice, Proxy Statement and proxy card or voting instruction form were enclosed. If you elected to receive your Special Meeting materials via e -mail , the e -mail contains voting instructions and links to the Proxy Statement, both of which are available on our website at https: // 60degreespharma.com . Additional details regarding admission to, and the business to be conducted at, the Special Meeting are described in the accompanying Notice and Proxy Statement. Only stockholders of record at the close of business on September 20, 2024 are entitled to notice of, and to vote at, the Special Meeting. Your vote is important. Regardless of whether you plan to attend the Special Meeting, we hope that you will vote as soon as possible. You may vote by telephone or by mailing in a proxy card. Please review the instructions on the proxy card or voting instruction form regarding each of these voting options. Voting will ensure your representation at the Special Meeting regardless of whether you attend the Special Meeting. Thank you for your on -going support of 60 Degrees Pharmaceuticals, Inc. Sincerely, / s / Geoffrey Dow     Geoffrey Dow     Chief Executive Officer and President       Table of Contents 60 DEGREES PHARMACEUTICALS, INC. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 https: // 60degreespharma.com NOTICE OF SPECIAL MEETING OF STOCKHOLDERS To Be Held Virtually at 12:30 P.M. (Eastern Time) on November 6, 2024 Notice is hereby given that a Special Meeting of Stockholders (the “Special Meeting”) of 60 Degrees Pharmaceuticals

View Full Filing

View this DEF 14A filing on SEC EDGAR